Announcement on Change of Accounting Policies
Filed with SSE · · 2 pages · Chinese
Harbin Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Harbin Pharmaceutical
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Resolutions of the 24th Meeting of the 10th Board of Directors
- Announcement on Subsidiary's Drug Passing the Consistency Evaluation for Generic Drugs
- Announcement on Affiliated Enterprise Obtaining Approval for Marketing of Chemical APIs
- Announcement on Subsidiary Obtaining Drug Registration Certificate
Later from Harbin Pharmaceutical
- Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2026 and the 2025 Annual and Q1 2026 Performance Briefing
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Pledge of Partial Shares of Controlling Shareholder
Follow Harbin Pharmaceutical into a list and get an email when it puts out news.
Follow Harbin Pharmaceutical